about
Vaccines for Acinetobacter baumannii: thinking "out of the box".Selectable Markers for Use in Genetic Manipulation of Extensively Drug-Resistant (XDR) Acinetobacter baumannii HUMC1.The future of antibioticsImportance of Tryptophan in Transforming an Amphipathic Peptide into a Pseudomonas aeruginosa-Targeted Antimicrobial Peptide.The evolution of the regulatory framework for antibacterial agentsBactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa.Joint Transcriptional Control of Virulence and Resistance to Antibiotic and Environmental Stress in Acinetobacter baumannii.Exploiting Interkingdom Interactions for Development of Small-Molecule Inhibitors of Candida albicans Biofilm Formation.Prioritized current unmet needs for antibacterial therapies.Evaluation of Parameters for High Efficiency Transformation of Acinetobacter baumannii.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.Genetic Regulation of Virulence and Antibiotic Resistance in Acinetobacter baumanniiLaboratory Maintenance of Acinetobacter baumannii.Enterobactin-mediated delivery of β-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli.Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.Targeting the Type II Secretion System: Development, Optimization, and Validation of a High-Throughput Screen for the Identification of Small Molecule Inhibitors.Combating virulence of Gram-negative bacilli by OmpA inhibition.The Capsular Polysaccharide of Acinetobacter baumannii Is an Obstacle for Therapeutic Passive Immunization Strategies.Narrow-Spectrum Antibacterial Agents.Activity of Pentamidine Alone and in Combination With Aminoglycosides, Tigecycline, Rifampicin, and Doripenem Against Clinical Strains of Carbapenemase-Producing and/or Colistin-Resistant EnterobacteriaceaeThe lytic transglycosylase MltB connects membrane homeostasis and in vivo fitness of Acinetobacter baumannii
P2860
Q33637895-E9806F44-90F6-46C0-92D6-7B499EA19675Q33649288-37517FA0-85B2-4AB2-A37D-EB46CA57FA4FQ33821520-39E982FB-45C1-4AC5-AD3A-604A5914C340Q34672675-CADD2173-269B-4291-98EF-9B83BC1DBE10Q34693386-51A9B349-809F-46B7-91BD-4ACC5B747F8CQ35607752-82F839AE-7686-40CC-8934-C908B37D3C91Q36318967-E3AF97FF-7754-47D3-A78E-D1932D0058AAQ37287904-1092D228-B0E9-40E4-968E-41512025FF86Q38233288-147EA6EC-0106-4F1F-9800-BFD9D4BE9E3FQ38622903-30EA23AA-7D9C-4A8A-9276-524980471449Q39038590-F9945E47-59CE-4F03-8D46-12D6708923DBQ39063044-86EF2D80-0CEA-442F-9C1C-FB1D993999CBQ41678796-35F7C028-3818-4132-B53B-7B4E1800436AQ42257669-B86FBDD0-0673-4B16-9D3A-E718A056C238Q43202091-900CE2E7-170A-4397-8285-28027893E3FCQ43563522-D97F2D0E-C6EC-4031-8745-3A74938FAFD4Q46308613-3C129603-AB6B-4C80-A7C6-92AA1AB3D6D1Q47094774-4F7B0467-ECFA-4BA2-94DF-3FE4E1D84227Q47744180-E5B7F412-AE75-4012-8C63-CF6E21E540C4Q53703028-3CEE7A7C-2499-49B6-874D-AF8DA6D64CABQ58595994-1BB5F311-FF22-48D4-8DE3-E9EAD10655B5Q59125140-071966BC-4824-47FB-89EC-03D6E420EB2E
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The value of single-pathogen antibacterial agents.
@en
The value of single-pathogen antibacterial agents.
@nl
type
label
The value of single-pathogen antibacterial agents.
@en
The value of single-pathogen antibacterial agents.
@nl
prefLabel
The value of single-pathogen antibacterial agents.
@en
The value of single-pathogen antibacterial agents.
@nl
P2860
P356
P1476
The value of single-pathogen antibacterial agents
@en
P2093
Brad Spellberg
P2860
P2888
P356
10.1038/NRD3957-C1
P50
P577
2013-11-15T00:00:00Z